Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Medicxi’s new €400M fund unites early, late stage investing

In age of megarounds, Medicxi is sticking with its asset-focused approach with its third fund

July 18, 2019 11:03 PM UTC

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle.

Medicxi III will deploy €400 million ($451.2 million) across all stages of development, from company creation through late-stage clinical assets that have already shown proof of concept. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Medicxi Ventures